Effects of Azilsartan, Aliskiren or Their Combination on High Fat Diet-induced Non-alcoholic Liver Disease Model in Rats

Overview

Journal Med Arch

Specialty General Medicine

Date 2017 Oct 5

PMID 28974844

Citations 6

Authors

Saad Abdulrahman Hussain

Rabab Mohammed Utba

Ajwad Muhammad Assumaidaee

Affiliations

Soon will be listed here.

Abstract

Introduction: In addition to its role in regulation of blood pressure, fluid and electrolyte homeostasis, the renin-angiotensin system (RAS) components were expressed in many other tissues suggesting potential roles in their functions.

Aim: The present study aims to evaluate the protective effect aliskiren, when used alone or in combination with azilsartan against high fat diet-induced liver disease in rats.

Material And Methods: Thirty-two Wistar male rats, weighing 150-200 gm were allocated evenly into four groups and treated as follow: group I, rats were fed a specially formulated high-fat diet for 8 weeks to induce non-alcoholic liver disease and considered as control group; groups II, III and IV, the rats were administered azilsartan (0.5 mg/kg), aliskiren (25 mg/kg) or their combination orally via gavage tube once daily, and maintained on high fat diet for 8 weeks. The possible treatment outcome was evaluated through measuring serum levels of glucose, insulin, lipid profile, TNF-α, IL-1β and liver enzymes. Additionally, the liver tissue contents of glycogen and lipids and histological changes were also evaluated.

Result: The results showed that azilsartan significantly improves the studied markers greater than aliskiren, and their combination o has no additive or synergistic effects on the activity of each one of them.

Conclusion: Both azilsartan and aliskiren protects the rats against high-fat diet induced NAFLD with predominant effects for the former, and their combination showed no beneficial synergistic or additive effects.

Citing Articles

Azilsartan as a preventive agent against cyclophosphamide-induced testicular injury in male rats.

Ahmed H, Gatea F, Hussein Z Naunyn Schmiedebergs Arch Pharmacol. 2024; 398(1):979-990.

PMID: 39093466 DOI: 10.1007/s00210-024-03339-6.

Implication of endoplasmic reticulum stress and mitochondrial perturbations in remote liver injury after renal ischemia/reperfusion in rats: potential protective role of azilsartan.

Elrashidy R, Zakaria E, Hasan R, Elmaghraby A, Hassan D, Abdelgalil R Redox Rep. 2024; 29(1):2319963.

PMID: 38411133 PMC: 10903753. DOI: 10.1080/13510002.2024.2319963.

Curative Effect of AD-MSCs against Cisplatin-Induced Hepatotoxicity in Rats is Potentiated by Azilsartan: Targeting Oxidative Stress, MAPK, and Apoptosis Signaling Pathways.

Bekhit A, Beshay O, Fawzy M, Abdel-Hafez S, El-Saber Batiha G, Ataya F Stem Cells Int. 2023; 2023:6767735.

PMID: 37908315 PMC: 10615573. DOI: 10.1155/2023/6767735.

Angiotensinogen in hepatocytes contributes to Western diet-induced liver steatosis.

Tao X, Rong J, Lu H, Daugherty A, Shi P, Ke C J Lipid Res. 2019; 60(12):1983-1995.

PMID: 31604805 PMC: 6889717. DOI: 10.1194/jlr.M093252.

Azilsartan improves the effects of etanercept in patients with active rheumatoid arthritis: a pilot study.

Mahmood N, Hussain S, Mirza R Ther Clin Risk Manag. 2018; 14:1379-1385.

PMID: 30122937 PMC: 6086094. DOI: 10.2147/TCRM.S174693.

References

Araujo A, Varela H, de Medeiros C, Brito G, de Lima K, de Moura L . Azilsartan reduced TNF-α and IL-1β levels, increased IL-10 levels and upregulated VEGF, FGF, KGF, and TGF-α in an oral mucositis model. PLoS One. 2015; 10(2):e0116799. PMC: 4331549. DOI: 10.1371/journal.pone.0116799. View

Zhao M, Li Y, Wang J, Ebihara K, Rong X, Hosoda K . Azilsartan treatment improves insulin sensitivity in obese spontaneously hypertensive Koletsky rats. Diabetes Obes Metab. 2011; 13(12):1123-9. DOI: 10.1111/j.1463-1326.2011.01471.x. View

Paul M, Poyan Mehr A, Kreutz R . Physiology of local renin-angiotensin systems. Physiol Rev. 2006; 86(3):747-803. DOI: 10.1152/physrev.00036.2005. View

Milic S, Mikolasevic I, Krznaric-Zrnic I, Stanic M, Poropat G, Stimac D . Nonalcoholic steatohepatitis: emerging targeted therapies to optimize treatment options. Drug Des Devel Ther. 2015; 9:4835-45. PMC: 4548724. DOI: 10.2147/DDDT.S64877. View

Takahashi N, Li F, Hua K, Deng J, Wang C, Bowers R . Increased energy expenditure, dietary fat wasting, and resistance to diet-induced obesity in mice lacking renin. Cell Metab. 2007; 6(6):506-12. PMC: 2174204. DOI: 10.1016/j.cmet.2007.10.011. View

Wu Y, Ma K, Zhang Y, Wen Y, Wang G, Hu Z . Lipid disorder and intrahepatic renin-angiotensin system activation synergistically contribute to non-alcoholic fatty liver disease. Liver Int. 2016; 36(10):1525-34. DOI: 10.1111/liv.13131. View

Jonsson J, Clouston A, Ando Y, Kelemen L, Horn M, Adamson M . Angiotensin-converting enzyme inhibition attenuates the progression of rat hepatic fibrosis. Gastroenterology. 2001; 121(1):148-55. DOI: 10.1053/gast.2001.25480. View

Lee K, Chan C, Yang Y, Hsieh Y, Huang Y, Lin H . Aliskiren attenuates steatohepatitis and increases turnover of hepatic fat in mice fed with a methionine and choline deficient diet. PLoS One. 2013; 8(10):e77817. PMC: 3804600. DOI: 10.1371/journal.pone.0077817. View

Qi N, Wang J, Zidek V, Landa V, Mlejnek P, Kazdova L . A new transgenic rat model of hepatic steatosis and the metabolic syndrome. Hypertension. 2005; 45(5):1004-11. DOI: 10.1161/01.HYP.0000161995.64192.2b. View

10.

Paschos P, Tziomalos K . Nonalcoholic fatty liver disease and the renin-angiotensin system: Implications for treatment. World J Hepatol. 2013; 4(12):327-31. PMC: 3554795. DOI: 10.4254/wjh.v4.i12.327. View

11.

Muller-Fielitz H, Hubel N, Mildner M, Vogt F, Barkhausen J, Raasch W . Chronic blockade of angiotensin AT₁ receptors improves cardinal symptoms of metabolic syndrome in diet-induced obesity in rats. Br J Pharmacol. 2014; 171(3):746-60. PMC: 3969086. DOI: 10.1111/bph.12510. View

12.

Pathak S, Goldofsky E, Vivas E, Bonagura V, Vambutas A . IL-1β is overexpressed and aberrantly regulated in corticosteroid nonresponders with autoimmune inner ear disease. J Immunol. 2011; 186(3):1870-9. PMC: 3031454. DOI: 10.4049/jimmunol.1002275. View

13.

Wang C, Li F, Takahashi N . The renin angiotensin system and the metabolic syndrome. Open Hypertens J. 2010; 3:1-13. PMC: 2995894. DOI: 10.2174/1876526203010001. View

14.

Kishina M, Koda M, Kato J, Tokunaga S, Matono T, Sugihara T . Therapeutic effects of the direct renin inhibitor, aliskiren, on non-alcoholic steatohepatitis in fatty liver Shionogi ob/ob male mice. Hepatol Res. 2013; 44(8):888-896. DOI: 10.1111/hepr.12186. View

15.

Greenberg A, McDaniel M . Identifying the links between obesity, insulin resistance and beta-cell function: potential role of adipocyte-derived cytokines in the pathogenesis of type 2 diabetes. Eur J Clin Invest. 2002; 32 Suppl 3:24-34. DOI: 10.1046/j.1365-2362.32.s3.4.x. View

16.

Chan T, EXTON J . A rapid method for the determination of glycogen content and radioactivity in small quantities of tissue or isolated hepatocytes. Anal Biochem. 1976; 71(1):96-105. DOI: 10.1016/0003-2697(76)90014-2. View

17.

Georgescu E . Angiotensin receptor blockers in the treatment of NASH/NAFLD: could they be a first-class option?. Adv Ther. 2008; 25(11):1141-74. DOI: 10.1007/s12325-008-0110-2. View

18.

Lee K, Hsieh Y, Yang Y, Chan C, Huang Y, Lin H . Aliskiren Reduces Hepatic steatosis and Epididymal Fat Mass and Increases Skeletal Muscle Insulin Sensitivity in High-Fat Diet-Fed Mice. Sci Rep. 2016; 6:18899. PMC: 4702081. DOI: 10.1038/srep18899. View

19.

Kang Y, Lee M, Song H, Hyun Y, Cha J, Ko G . Aliskiren improves insulin resistance and ameliorates diabetic vascular complications in db/db mice. Nephrol Dial Transplant. 2010; 26(4):1194-204. DOI: 10.1093/ndt/gfq579. View

20.

Velkoska E, WARNER F, Cole T, Smith I, Morris M . Metabolic effects of low dose angiotensin converting enzyme inhibitor in dietary obesity in the rat. Nutr Metab Cardiovasc Dis. 2009; 20(1):49-55. DOI: 10.1016/j.numecd.2009.02.004. View